skinny.

Latest / The HemOnc Pulse

Dr. Venugopal Offers Her Thoughts on the Latest MDS News

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease. She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.